Simeone et al. found that decreasing levels of CRP from baseline to week 12 significantly correlated with better disease control rate and longer overall survival in metastatic melanoma patients treated with the anti- CTLA4 agent ipilimumab [37]. The gene discussed is CTLA4; the disease is metastatic melanoma.